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lowed by either autologous or allogeneic transplant. We report
modest TRM, high CR rates and favorable survival following
allogeneic transplants. Younger patients with responsive disease
undergoing early transplant may have a superior survival and lower
TRM. This group may be suitable candidates for allogeneic trans-
plant.
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FOR HISTOLOGICALLY TRANSFORMED LOW-GRADE FOLLICULAR NON-
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gasia, M.1, Kassim, A.1, Mineshi, S.1, Morgan, D.S.1, Ruffner, K.1,
Friedrich, S.G.1, Shyr, Y.2, Goodman, S.A.1 1. Division of Hematology/
Oncology, Vanderbilt University Medical Center and Veterans Admin-
istration Medical Center, Nashville, TN; 2. Department of Biostatistics,
Vanderbilt University Medical Center, Nashville, TN
Introduction: Histological transformation of low-grade follicu-
lar NHL to a higher grade occurs in greater than 50% of patients
during the course of their disease. Historically, prognosis of these
patients is poor following conventional chemotherapy with median
survival of less than a year. SCT following dose intensiﬁcation has
been shown in few studies to improve the survival in such patients.
Methods: We performed a retrospective review of the pathology
of 367 adult NHL patients who underwent high-dose chemother-
apy and SCT at our institution between 1992 and 2002. We
identiﬁed 34 patients with follicular low-grade NHL who had
transformed to intermediate grade disease (diffuse large cell or
transformed large cell-REAL grade III). Patients with transforma-
tion to high grade or immunoblastic NHL were excluded. Results:
Thirty-one patients underwent autologous and 3 underwent allo-
geneic SCT. Median age at transplant was 53 years (35-69). 70% of
patients were male. 26% (9/34) patients had transformed disease at
diagnosis (had concurrent low-grade histology) and 74% (25/34)
had transformation at ﬁrst relapse. The median time to transfor-
mation from low to intermediate grade was 930 days (630-5430
days). 85% of the patients had advanced disease (stage III-IV) at
transformation. Median number of treatments for transformed
disease prior to SCT was 2 (1-6). 24 patients were in a partial
remission (PR), 6 in a complete remission (CR) and 4 had stable
disease at time of SCT. 76% (26/34) patients received a non-TBI
based conditioning regimen; 85% received peripheral blood stem
cells with a median CD34 dose of 3.45  106/kg. All patients
showed normal engraftment. Survival at 100 days was 97%
(95%CI 91%-100%), the only peri-SCT death occurred in the
allogeneic group. Median overall survival (OS) from SCT was 48
months (95%CI 38 mo-not reached) and 4-year OS was 49%.
Median disease free survival (DFS) from SCT was 20 months
(95%CI of 10-57months) with a 4-year DFS of 18%. The number
of prior therapies and time to transformation had no impact on the
survival. Subgroup of patients with stable disease (no response to
chemotherapy) prior to SCT had the worst outcome. Conclusion:
Our survival data indicates that one-half of patients with trans-
formed NHL will survive 4 years and one third of the survivors will
be disease free. SCT should be considered for eligible patients with
chemosensitive histologically transformed NHL.
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UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION AF-
TER NONMYELOABLATIVE CONDITIONING FOR PATIENTS WITH POOR
RISK, RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Georges, G.E.1, Maris, M.B.1, Sandmaier, B.M.1, Stuart, M.J.2, Nied-
erwieser, D.3, Agura, E.4, Bruno, B.5, McSweeney, P.6, Anasetti, C.1,
Storb, R.1, Maloney, D.G.1 1. Fred Hutchinson Cancer Research Center
and Univerisity of Washington, Seattle, WA; 2. Stanford University,
Palo Alto, CA; 3. University of Leipzig, Germany; 4. Baylor University,
Dallas, TX; 5. University of Torino, Italy; 6. University of Colorado,
Denver, CO
We investigated the feasibility of HLA-matched unrelated donor
(URD) hematopoietic cell transplantation (HCT) in patients with
advanced stage, poor-risk multiple myeloma after nonmyeloabla-
tive conditioning. Eighteen patients, median age 53 years (range,
29-66), were enrolled between 5/2000 and 12/2002. At study entry,
12 patients had relapsed/refractory disease after a preceding autol-
ogous HCT, 5 patients had refractory disease following multiple
standard chemotherapy regimens, and 1 patient achieved a partial
remission (PR) after standard chemotherapy. Nine patients under-
went a planned high dose autologous HCT (Melphalan 200 mg/
m2) a median of 75 days prior to URD HCT, including 4 of the 12
patients with relapsed/refractory disease after prior failed autolo-
gous HCT. Two of the 18 patients were in complete remission
(CR, IBMTR/ABMTR criteria) immediately prior to URD HCT.
Nonmyeloablative conditioning consisted of ﬂudarabine (30 mg/
m2  3 days) and 2 Gy total body irradiation. A median of 8.6 
106 CD34/kg G-CSF-stimulated peripheral blood mononuclear
cells were transplanted from URDs matched for HLA-A, -B, -C
antigens and -DRB1 and -DQB1 alleles. Postgrafting immunosup-
pression included mycophenolate mofetil and cyclosporine. Dura-
ble engraftment was achieved in 17 of 18 patients. Acute GVHD
occurred in 13 (72%) patients and was exclusively grades II and III
in 11 and 2 patients, respectively. Chronic extensive GVHD oc-
curred in 11/16 (69%) of evaluable patients. After allografting, 7
patients (39%) achieved CR and 3 (17%) achieved PR, for an
overall response rate of 56%. Three patients (17%) died of pro-
gressive disease and 4 patients (22%) died of non-relapse causes at
a median of 5 months after URD HCT. With a median follow-up
of 15 months after URD HCT, 11 of 18 patients (61%) were alive,
6 (33%) in CR, 2 (11%) in PR and 3 (17%) with stable disease
(SD). Of the 9 patients who underwent a planned high dose
autologous HCT followed by URD HCT, 7 were alive: 5 in CR,
1 in PR and 1 with SD. In summary, URD HCT after nonmy-
eloablative conditioning is feasible with a relatively low non-re-
lapse mortality and provides a high response rate for patients with
relapsed or refractory multiple myeloma. The data also suggest
that intensive cytoreductive therapy (autologous HCT) followed
by URD HCT may be an effective salvage approach for treating
patients with poor risk, chemotherapy refractory multiple my-
eloma or after failed prior autologous HCT.
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NO ADVANTAGE FOR MORE THAN 4 CYCLES OF VAD PRIOR TO AU-
TOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA
Rodriguez, C.P., Bolwell, B., Ronald, S., Pohlman, B., Rybicki, L.,
Kalaycio, M.E. Department of Hematology and Medical Oncology,
Cleveland Clinic Foundation, Cleveland, OH
Patients with myeloma are typically treated with several cycles of
infusional vincristine, doxorubicin and dexamethasone (VAD)
prior to autologous stem cell transplant. We reviewed our experi-
ence to determine if an optimal number of VAD cycles (Vincristine
0.4 mg/day IV days 1-4, Doxorubicin 9mg/m2/day IV days 1-4,
Dexamethasone 40mg PO days 1-4, 9-12, 17-20) could be identi-
ﬁed. The records of 95 patients who underwent autologous pe-
ripheral stem cell transplantation for multiple myeloma from 1989
to 2001 were reviewed. Data on each patient’s pretransplant che-
motherapy regimen, response to initial chemotherapy and toxicity
during transplantation were obtained. Seven patients who suffered
relapse after initial chemotherapy were excluded during the data
analysis. The Kaplan Meier method was used to estimate survival
in the remaining 88 patients. Of the 88 patients treated, 62 were
treated with VAD for a median of 4 cycles (range 1-9) before
transplant. Thirty six patients were treated with 4 cycles of VAD,
9 were treated with less than 4 cycles, 15 received more than 4
cycles and two received an unknown number of cycles. Fourteen
patients received VAD either before of after other chemotherapy
regimens. Of the 26 patients who were treated with regimens other
than VAD, most included melphalan. One patient received an
unknown type of chemotherapy. Patients had to demonstrate at
least a partial remission in order to proceed with transplantation.
Autologous stem cells were harvested after GCSF mobilization. All
patients were admitted to the hospital and were treated with Busul-
fan (1mg/kg every 6 hours for 16 doses, days 1 to 4) and Cyclo-
phosphamide (60 mg/kg daily for 2 doses). GCSF was given after
transplant in addition to other standard supportive care practices.
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The time to ANC 500 ranged from 8 to 19 days with a median
of 10 days. The median length of stay was 21 days. Three patients
experienced early treatment-related mortality. With median follow
up of 21 months, 45 patients have relapsed. The ﬁve year disease
free survival (DFS) is 26% and overall survival (OS) is 58%.
Thirty-nine patients (44%) remain alive and disease free. There
was no difference in DFS (P  .82)or OS (p  .55) between those
patients who received 4 cycles of VAD compared to those who
received any other number of VAD cycles. There appears to be no
advantage to giving anything more than 4 cycles of VAD before
proceeding to stem cell transplant.
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THALIDOMIDE MAINTENANCE AFTER AUTOLOGOUS STEM CELL
TRANSPLANTATION FOR MULTIPLE MYELOMA
Grosskreutz, C.L., Egan, R., Scigliano, E., Fruchtman, S.M., Isola,
L.M. Mount Sinai Medical Center, New York, NY
Autologous stem cell transplantation (ASCT) for multiple my-
eloma (MM) results in a slow and progressive decline in progres-
sion free survival. Thalidomide is an effective salvage agent in
patients who relapse with MM after ASCT and produces no my-
elosuppression. Therefore, it is an attractive drug for maintenance
post-ASCT. We gave thalidomide to 21 patients after ASCT for
MM. Patients received therapy with VAD chemotherapy until
maximal response (maximum 4 cycles), mobilization with cyclo-
phosphamide 4000 mg/m2 and G-CSF 10 mcg/kg/day and autol-
ogous collection followed by ASCT after high dose chemotherapy
with melphalan 200 mg/m2. The median age was 57; the M/F ratio
was 1.6/1. Thalidomide was started upon recovery of counts but no
earlier than day 30 post-ASCT. The initial dose was 200 mg QD
and it was incremented by 200 mg every 2 weeks to a maximum of
800 mg QD. Patients who reported intolerance to the higher dose
were tapered to the prior highest tolerated dose and maintained on
it. The monoclonal gammopathy was IgG in 20 patients and Ig A
in 1 patient. Eleven patients underwent one ASCT and 10 had
tandem transplants. The highest sustained dose of thalidomide was
800 mg and the median was 200mg. Therapy was given for 85 to
1306 days (median 357). The median time of follow up was 474
days (range 131 to 2842). The median pre-ASCT, pre-thalidomide
and post-thalidomide monoclonal immunoglobulin (Ig) levels were
1320 mg/dl, 1200 mg/dl and 1430 mg/dl respectively. For those
progresing on thalidomide the average increase on Ig level was
49.9%. In the entire cohort, 13 patients responded whereas 8
progressed. Thalidomide in a dose of at least 200 mg QD was well
tolerated as maintenance post-ASCT in all patients. However,
several patients (38%) relapsed while receiving the drug. A ran-
domized placebo controlled study, stratiﬁed by known risks for
relapse post ASCT is warranted to determine whether thalidomide
maintenance delays the progression of myeloma after ASCT.
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PRE-APHERESIS THERAPIES AFFECTING CD34 APHERESIS YIELD IN
MULTIPLE MYELOMA PATIENTS
Malone, C.1, Paivanas, N.1, Spiros, A.R.1, Spira, A.I.1, Orloff, G.J.1,
Torloni, S.A.2, Sheridan, M.J.2, Beveridge, R.A.1 1. Fairfax Stem Cell
Transplant Program INOVA Fairfax Hospital Cancer Center, Fairfax,
VA; 2. INOVA Fairfax Hospital, Fairfax, VA
Rationale: We posited that the number of cycles of pre-trans-
plant chemotherapies and/or with radiation (RT) directly impacts
both the procedural CD34 cell yield, and in the number of days
of apheresis required to harvest an overall adequate number of CD
34 cells. Methods: A retrospective analysis of 47 charts from
patients over a 2 year period with multiple myeloma was con-
ducted. We analyzed them for: the type and number of cycles of
chemotherapy, age, sex, and prior radiation therapy. Patients were
sorted into those receiving 4-6 cycles of VAD and those receiving
any other therapies in addition to or instead of VAD. Patients
receiving adjuvant RT similarly divided. Median days-to-adequate-
stem-cell-yield was determined. Cell viability of the apheresis
product was correlated with days-to-white-blood-cell engraftment.
Results: Patients who received VAD only required less apheresis
than those receiving other therapies (median 1 vs. 2 days, p 
0.015). There was no data to suggest that age or sex correlated with
the duration of apheresis. There was no correlation between cell
viability and days-to-white-blood-cell engraftment. Patients re-
ceiving RT in addition to VAD required a median of 1 day of
apheresis. A single patient receiving additional chemotherapy
along with radiation required 4 days of apheresis. Conclusion:
Patients receiving 4-6 cycles of VAD alone had faster adequate
apheresis yields compared with those receiving additional or other
regimens. Radiation did not appear to have an effect on patient’s
CD34 yield who also received VAD as therapy. Further studies
should be pursued to determine the effects of other adjuvant
chemotherapies to VAD, and in patients receiving radiation, in
predicting time to CD34 apheresis yield.
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HLA-MATCHED RELATED (MRD) OR UNRELATED DONOR (URD) NON-
MYELOABLATIVE CONDITIONING AND HEMATOPOIETIC CELL TRANS-
PLANT (HCT) FOR PATIENTS WITH ADVANCED HODGKIN DISEASE
(HD)
Burroughs, L.M.1,2, Maris, M.B.1,3, Sandmaier, B.M.1,3, Leisenring,
W.1,4,5, Jain Stuart, M.6, Niederwieser, D.7, McSweeney, P.A.8,
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of Pediatrics, University of Washington, Seattle, WA; 3. Department of
Medicine, University of Washington, Seattle, WA; 4. Public Health
Sciences Division, Fred Hutchinson Cancer Research Center, Seattle,
WA; 5. Department of Biostatistics, University of Washington, Seattle,
WA; 6. Stanford University, Palo Alto, CA; 7. University of Leipzig,
Leipzig, Germany; 8. University of Colorado, Denver, CO; 9. Seattle
Veterans Administration Medical Center, Seattle, WA; 10. Oregon
Health & Sciences University, Portland, OR; 11. Baylor University,
Dallas, TX
Patients (pts) with progressive HD following autologous HCT
have limited treatment options and poor prognosis. We evaluated
the utility of nonmyeloablative conditioning and allogeneic HCT
for pts ineligible for high dose conventional allogeneic HCT due
to age and/or comorbidities. Between December 1998 and Octo-
ber 2002, 27 pts (18 MRD, 9 URD) received 2 Gy total body
irradiation alone (n  7 MRD) or with 90 mg/m2 ﬂudarabine (n 
11 MRD, n  9 URD), G-CSF mobilized peripheral blood HCT
and postgrafting immunosuppression with mycophenolate mofetil
and cyclosporine. Median age was 37 (range 21-65) years. Pts were
heavily pretreated and had advanced disease with a median number
of prior regimens of 5 (range 2-9). Most pts had prior radiation
therapy (25/27) and prior high dose autologous HCT (24/27).
Median time between autologous HCT and salvage therapy was 8
(range 2-73) months. Median time between autologous HCT and
allogeneic HCT was 16 (range 2-78) months. At allogeneic HCT,
5 pts were in complete remission (CR), 11 in partial remission
(PR), 4 had relapsed disease and 7 had refractory disease. All pts
engrafted and there were no graft rejections. The overall incidence
of acute Grade II, III, and IV GVHD was 33%, 15%, and 4%
respectively. Incidence of chronic extensive GVHD was 55% at 1
year. The overall response rate, deﬁned as those pts with measur-
able disease prior to transplant who achieved a CR or PR after
allogeneic HCT was 55%. Currently, 9 of 27 pts are alive; 6 are in
CR and 3 have relapsed or have progressive disease (PD), with a
Table. Median Days of Apheresis Required: Patients Receiving VAD
vs. Receiving VAD  Other Adjuvant Therapy
Chemotherapy
Only
Median
Days of
Apheresis
Radiation 
Chemotherapy
Median
Days of
Apheresis
VAD only (n  25) 1 RT  VAD
(n  5)
1
Other (n  22) 2 RT  other
chemo (n  1)
4
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